

# Bertrand Knebelmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10744759/publications.pdf>

Version: 2024-02-01

65  
papers

5,272  
citations

94433

37  
h-index

98798

67  
g-index

70  
all docs

70  
docs citations

70  
times ranked

5284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	2.9	3
2	Erythrocytosis associated with IgA nephropathy. EBioMedicine, 2022, 75, 103785.	6.1	2
3	COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. Nephrology Dialysis Transplantation, 2022, 37, 1357-1365.	0.7	17
4	The 2019 and 2021 International Workshops on Alport Syndrome. European Journal of Human Genetics, 2022, 30, 507-516.	2.8	12
5	Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease. Clinical Genetics, 2022, 101, 390-402.	2.0	26
6	Efficacy of Prolonged Antibiotic Therapy for Renal Cyst Infections in Polycystic Kidney Disease. Mayo Clinic Proceedings, 2022, 97, 1305-1317.	3.0	0
7	Cystinuria: clinical practice recommendation. Kidney International, 2021, 99, 48-58.	5.2	58
8	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. American Journal of Nephrology, 2021, 52, 180-189.	3.1	31
9	Defects in KCNJ16 Cause a Novel Tubulopathy with Hypokalemia, Salt Wasting, Disturbed Acid-Base Homeostasis, and Sensorineural Deafness. Journal of the American Society of Nephrology: JASN, 2021, 32, 1498-1512.	6.1	46
10	FC 0104-WEEK ANTIBIOTIC THERAPY PREVENTS RECURRENT RENAL CYST INFECTIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
11	Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency. Transplantation, 2020, 104, 2120-2128.	1.0	10
12	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	5.2	27
13	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood, 2020, 135, 1833-1846.	1.4	42
14	AA amyloidosis associated with Fabry disease. International Journal of Clinical Practice, 2020, 74, e13577.	1.7	1
15	Red Blood Cell AE1/Band 3 Transports in Dominant Distal Renal Tubular Acidosis Patients. Kidney International Reports, 2020, 5, 348-357.	0.8	11
16	APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrology Dialysis Transplantation, 2019, 34, 1885-1893.	0.7	12
17	Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France. BJU International, 2019, 124, 849-861.	2.5	30
18	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood, 2019, 133, 576-587.	1.4	78

#	ARTICLE	IF	CITATIONS
19	mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. <i>Kidney International</i> , 2019, 95, 455-466.	5.2	44
20	Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. <i>Kidney International</i> , 2018, 93, 716-726.	5.2	46
21	Multiplex epithelium dysfunction due to CLDN10 mutation: the HELIX syndrome. <i>Genetics in Medicine</i> , 2018, 20, 190-201.	2.4	75
22	The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. <i>Kidney International</i> , 2017, 91, 720-728.	5.2	43
23	Clinical and Genetic Spectrum of Bartter Syndrome Type 3. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2540-2552.	6.1	92
24	Clinical and molecular characterization of cystinuria in a French cohort: relevance of assessing large-scale rearrangements and splicing variants. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2017, 5, 373-389.	1.2	22
25	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2099.	7.4	120
26	Observations of a large Dent disease cohort. <i>Kidney International</i> , 2016, 90, 430-439.	5.2	71
27	Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. <i>Nature Communications</i> , 2016, 7, 10330.	12.8	88
28	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 337-348.	0.7	206
29	Screening for Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Survey of 420 Nephrologists. <i>PLoS ONE</i> , 2016, 11, e0153176.	2.5	17
30	A New Workflow for Proteomic Analysis of Urinary Exosomes and Assessment in Cystinuria Patients. <i>Journal of Proteome Research</i> , 2015, 14, 567-577.	3.7	39
31	Evidence of digenic inheritance in Alport syndrome. <i>Journal of Medical Genetics</i> , 2015, 52, 163-174.	3.2	129
32	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. <i>Kidney International</i> , 2015, 88, 1135-1143.	5.2	104
33	Light and heavy chain deposition disease associated with CH1 deletion. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 237-239.	2.9	12
34	Mutation Update of the <i>CLCN5</i> Gene Responsible for Dent Disease 1. <i>Human Mutation</i> , 2015, 36, 743-752.	2.5	66
35	CKD and Its Risk Factors among Patients with Cystinuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 842-851.	4.5	71
36	Autosomal dominant polycystic kidney disease: the changing face of clinical management. <i>Lancet</i> , The, 2015, 385, 1993-2002.	13.7	227

#	ARTICLE	IF	CITATIONS
37	Improving Mutation Screening in Familial Hematuric Nephropathies through Next Generation Sequencing. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2740-2751.	6.1	130
38	2,8-Dihydroxyadenine Urolithiasis: A Not So Rare Inborn Error of Purine Metabolism. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 241-252.	1.1	16
39	Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. <i>Pediatric Nephrology</i> , 2013, 28, 5-11.	1.7	118
40	Adenine Phosphoribosyltransferase Deficiency. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1521-1527.	4.5	87
41	Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. <i>Kidney International</i> , 2012, 81, 494-501.	5.2	275
42	Phenotype and Outcome in Hereditary Tubulointerstitial Nephritis Secondary to UMOD Mutations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2429-2438.	4.5	109
43	Phenotype and Genotype Characterization of Adenine Phosphoribosyltransferase Deficiency. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 679-688.	6.1	112
44	Spectrum of HNF1B Mutations in a Large Cohort of Patients Who Harbor Renal Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1079-1090.	4.5	236
45	Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. <i>Journal of Clinical Investigation</i> , 2010, 120, 4065-4076.	8.2	310
46	Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1183-1189.	4.5	186
47	Rituximab in Severe Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 579-587.	4.5	151
48	Enzyme therapy for Fabry's disease: registered for success?. <i>Lancet, The</i> , 2009, 374, 1950-1951.	13.7	3
49	Complete Remission of Lupus Nephritis With Rituximab and Steroids for Induction and Rituximab Alone for Maintenance Therapy. <i>American Journal of Kidney Diseases</i> , 2008, 52, 346-352.	1.9	25
50	Reversible paraparesis in multiple myeloma with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1439-1440.	0.7	4
51	Laminin 5 Regulates Polycystic Kidney Cell Proliferation and Cyst Formation. <i>Journal of Biological Chemistry</i> , 2006, 281, 29181-29189.	3.4	40
52	Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. <i>Kidney International</i> , 2005, 67, 2422-2433.	5.2	58
53	Impaired formation of desmosomal junctions in ADPKD epithelia. <i>Histochemistry and Cell Biology</i> , 2005, 124, 487-497.	1.7	35
54	Thalidomide in patients with multiple myeloma and renal failure. <i>British Journal of Haematology</i> , 2004, 125, 96-97.	2.5	45

#	ARTICLE	IF	CITATIONS
55	Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urological Research, 2003, 31, 207-211.	1.5	58
56	Î²4 Integrin and Laminin 5 Are Aberrantly Expressed in Polycystic Kidney Disease. American Journal of Pathology, 2003, 163, 1791-1800.	3.8	58
57	X-Linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2003, 14, 2603-2610.	6.1	394
58	Mesangial IgG Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 379-387.	6.1	15
59	X-linked Alport Syndrome. Journal of the American Society of Nephrology: JASN, 2000, 11, 649-657.	6.1	455
60	Genetic Diagnosis and Counseling in Inherited Renal Diseases. , 1998, , 685-694.		0
61	Autosomal recessive Alport syndrome: Immunohistochemical study of type IV collagen chain distribution. Kidney International, 1995, 47, 1142-1147.	5.2	155
62	Splice-mediated insertion of an Alu sequence in the COL4A3 mRNA causing autosomal recessive Alport syndrome. Human Molecular Genetics, 1995, 4, 675-679.	2.9	114
63	Aberrant splicing of the COL4A5 gene in patients with Alport syndrome. Human Molecular Genetics, 1994, 3, 317-322.	2.9	37
64	A molecular approach to inherited kidney disorders. Kidney International, 1993, 44, 1205-1216.	5.2	21
65	Alport syndrome and diffuse leiomyomatosis: Deletions in the 5â€™ end of the COL4A5 collagen gene. Kidney International, 1992, 42, 1178-1183.	5.2	91